# Central Dermatology

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/central-dermatology/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 59 |
| Citations | 34,861 |
| City | St Louis |
| Country | US |
| Description | Central Dermatology is a research organisation in St Louis, US. OpenAlex records 807 works and 34,861 citations for it. 125 researchers list it as their most recent affiliation. |
| Homepage | http://www.centralderm.com/ |
| OpenAlex ID | https://openalex.org/I4210134328 |
| Region | Missouri |
| Researchers | 125 |
| ROR ID | https://ror.org/03h9hv091 |
| Type | other |
| Works | 807 |

## University papers

- [Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)](https://scholariq.org/papers/efficacy-and-safety-of-ustekinumab-a-human-interleukin-12-23-monoclonal-antibody/)
- [Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis/)
- [Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial](https://scholariq.org/papers/adalimumab-therapy-for-moderate-to-severe-psoriasis-a-randomized-controlled/)
- [Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis](https://scholariq.org/papers/phase-3-trials-of-ixekizumab-in-moderate-to-severe-plaque-psoriasis/)
- [Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis-2/)
- [Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies](https://scholariq.org/papers/joint-american-academy-of-dermatology-national-psoriasis-foundation-guidelines/)
- [Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures](https://scholariq.org/papers/joint-aad-npf-guidelines-of-care-for-the-management-and-treatment-of-psoriasis-3/)
- [Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis](https://scholariq.org/papers/guselkumab-an-il-23-specific-mab-demonstrates-clinical-and-molecular-response-in/)
- [Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council](https://scholariq.org/papers/recategorization-of-psoriasis-severity-delphi-consensus-from-the-international/)

## University top topics

Showing 8 of 25.

- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Autoimmune Bullous Skin Diseases](https://scholariq.org/topics/autoimmune-bullous-skin-diseases/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)
- [Cancer and Skin Lesions](https://scholariq.org/topics/cancer-and-skin-lesions/)
- [Cutaneous lymphoproliferative disorders research](https://scholariq.org/topics/cutaneous-lymphoproliferative-disorders-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.